Our Pricing

Wegovy UK Cost: Lowest Prices Starting From £69.00

Published on: June 03, 2026

Searching for transparent wegovy uk cost lowest price information? At Cured Pharmacy, Wegovy (semaglutide) weight loss injections start from £79.00 with upfront pricing shown before your free online consultation. Our UK-registered clinical team provides genuine MHRA-licensed medication with discreet next-day delivery across the UK.

Understanding Wegovy UK Cost and Pricing Structure

Wegovy pricing in the UK varies significantly between providers, but at Cured Pharmacy, we guarantee the lowest cost starting from £79.00 per pen. This transparent pricing includes your medication, free clinical consultation with a UK prescriber, and discreet delivery to your door. Unlike some providers who hide costs until after consultation, we display all prices upfront so you can make informed decisions about your weight loss treatment.

The cost of Wegovy reflects the dose prescribed by your clinician, which typically increases gradually over 16-20 weeks following the MHRA-approved titration schedule [1]. Your UK prescriber will determine the appropriate starting dose during your free online assessment, which takes under 3 minutes to complete. All Wegovy supplied by Cured Pharmacy is sourced directly from UK-licensed wholesalers and carries full MHRA approval.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [2]. By activating GLP-1 receptors in the brain, pancreas, and digestive system, semaglutide helps regulate appetite, slow gastric emptying, and improve blood sugar control. This multi-pathway approach addresses the biological drivers of weight gain rather than simply suppressing hunger.

In the landmark STEP 1 clinical trial, participants using Wegovy 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. Notably, 83.5% of participants lost at least 5% of their baseline weight, and 66.1% achieved 10% or greater weight reduction. These results represent some of the most significant weight loss outcomes ever recorded in pharmaceutical trials for obesity management.

Clinical Evidence Supporting Wegovy

The STEP clinical trial programme included over 4,500 participants across multiple studies, demonstrating consistent weight loss outcomes across diverse populations [2][3]. STEP 2 specifically examined patients with type 2 diabetes, showing an average 9.6% weight reduction alongside improved glycaemic control. Importantly, participants also experienced improvements in cardiovascular risk markers, including blood pressure, cholesterol levels, and inflammatory markers [3].

Long-term data from the STEP 5 trial followed participants for 104 weeks, confirming sustained weight loss with continued semaglutide treatment [4]. Average weight reduction at two years reached 15.2%, with most participants maintaining their weight loss throughout the study period. These findings address a critical challenge in obesity management: maintaining weight loss over extended periods.

Wegovy Dosing Schedule and Cost Per Month UK

Wegovy treatment follows a structured dose escalation protocol approved by the MHRA to minimise gastrointestinal side effects [1]. You'll typically start with 0.25mg weekly for four weeks, then increase to 0.5mg, 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly. This gradual titration allows your body to adjust to the medication whilst reducing the likelihood of nausea, vomiting, or diarrhoea.

Monthly costs vary depending on your current dose in the titration schedule. At Cured Pharmacy, we provide clear pricing for each dose strength before you begin treatment, with prices starting from £79.00. Most patients reach the full 2.4mg maintenance dose within 16-20 weeks and continue at this dose for ongoing weight management, subject to regular review by their UK prescriber.

How Long Should You Take Wegovy?

NICE guidance recommends reviewing treatment response after 6 months of Wegovy therapy [5]. If you've achieved less than 5% weight loss by this point, your prescriber may discuss alternative approaches or address potential barriers to weight loss. For those responding well, Wegovy can be continued long-term as part of a comprehensive weight management programme including dietary changes and increased physical activity.

Clinical trials demonstrate that stopping Wegovy typically results in weight regain, highlighting that obesity is a chronic condition requiring ongoing management [4]. Your UK prescriber will work with you to determine the appropriate treatment duration based on your individual weight loss goals, side effect tolerance, and overall health improvements.

Wegovy vs Other Weight Loss Treatments: Cost and Effectiveness

Several prescription weight loss medications are available in the UK, each with different mechanisms, efficacy profiles, and cost structures. Understanding these differences helps you and your prescriber choose the most appropriate treatment for your circumstances. All options available through Cured Pharmacy require clinical assessment by a UK-registered prescriber before dispensing.

Semaglutide-based treatments like Wegovy work through GLP-1 receptor activation, whilst newer dual-action medications target both GLP-1 and GIP receptors for potentially greater weight loss [6]. Older treatments like orlistat work by blocking fat absorption in the digestive system, offering a non-injectable alternative but typically producing more modest weight loss results. Your prescriber will consider your medical history, weight loss goals, injection tolerance, and budget when recommending treatment.

Who Can Use Wegovy? Eligibility and Prescriber Assessment

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. Your UK prescriber will calculate your BMI during the online consultation and review your medical history to ensure Wegovy is safe and appropriate for you.

Certain medical conditions contraindicate Wegovy use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease [1]. Pregnant or breastfeeding individuals should not use Wegovy, and women of childbearing potential should use effective contraception during treatment. Your online assessment with Cured Pharmacy's UK clinical team screens for these contraindications before prescribing.

Common side effects include nausea, diarrhoea, vomiting, constipation, and abdominal pain, particularly during dose escalation [2]. These effects typically diminish over time as your body adjusts to the medication. More serious but rare side effects include pancreatitis, gallbladder problems, and changes in heart rate. Your prescriber will discuss these risks during consultation and provide guidance on managing side effects if they occur.

Medical Conditions That May Affect Wegovy Suitability

Patients with a history of pancreatitis should discuss this carefully with their prescriber, as GLP-1 receptor agonists have been associated with acute pancreatitis in rare cases [1]. Those with diabetic retinopathy should be monitored closely, particularly if rapid weight loss and improved glycaemic control occur together. Kidney function should be assessed before starting treatment, as severe gastrointestinal side effects can lead to dehydration and acute kidney injury in susceptible individuals.

If you're currently taking other medications for diabetes, blood pressure, or cholesterol, your prescriber may need to adjust doses as you lose weight and your metabolic health improves. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and our clinical team review all potential drug interactions during your online assessment to ensure safe, effective treatment.

How to Order Wegovy Online UK from Cured Pharmacy

Ordering Wegovy from Cured Pharmacy is straightforward and fully compliant with UK pharmacy regulations. Start by completing our free online consultation, which takes under 3 minutes and covers your medical history, current medications, and weight loss goals. A UK-registered prescriber reviews your assessment, typically within 24 hours, and approves your prescription if Wegovy is clinically appropriate for you.

Once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and shipped in 100% discreet packaging with next-day delivery available across the UK. All medication is sourced from UK-licensed wholesalers and carries full MHRA approval. You'll receive clear instructions on injection technique, dose escalation, and what to expect during treatment.

We provide ongoing support throughout your weight loss journey. If you experience side effects or have questions about your treatment, our pharmacy team is available by phone at (+44) 116 4646009 during business hours. Regular follow-up consultations ensure your treatment remains safe and effective, with dose adjustments made as needed by your UK prescriber.

Scientific References

1. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
7. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
8. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.